Risk Prediction Scores for Recurrence and Progression of Non-Muscle Invasive Bladder Cancer: An International Validation in Primary Tumours by Vedder, M.M. et al.
Risk Prediction Scores for Recurrence and Progression of
Non-Muscle Invasive Bladder Cancer: An International
Validation in Primary Tumours
Moniek M. Vedder1, Mirari Ma´rquez2, Esther W. de Bekker-Grob1, Malu L. Calle3, Lars Dyrskjøt4,
Manoils Kogevinas5, Ulrika Segersten6, Per-Uno Malmstro¨m6, Ferran Algaba7, Willemien Beukers8,
Torben F. Ørntoft4, Ellen Zwarthoff8, Francisco X. Real9,10, Nuria Malats2, Ewout W. Steyerberg1*
1Department of Public Health, Erasmus Medical Centre, Rotterdam, the Netherlands, 2Genetic and Molecular Epidemiology Group, Spanish National Cancer Research
Centre (CNIO), Madrid, Spain, 3 Systems Biology Department, University of Vic, Vic, Barcelona, Spain, 4Department of Molecular Medicine, Aarhus University Hospital,
Aarhus, Denmark, 5Centre for Research in Environmental Epidemiology, Municipal Institute of Medical Research, Barcelona, Spain, 6Department of Surgical Sciences,
Uppsala University, Uppsala, Sweden, 7Department of Pathology, Fundacio´ Puigvert-University Autonomous, Barcelona, Spain, 8Department of Pathology, Erasmus
Medical Centre, Rotterdam, the Netherlands, 9 Epithelial Carcinogenesis Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain, 10Department of
Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain
Abstract
Objective: We aimed to determine the validity of two risk scores for patients with non-muscle invasive bladder cancer in
different European settings, in patients with primary tumours.
Methods: We included 1,892 patients with primary stage Ta or T1 non-muscle invasive bladder cancer who underwent a
transurethral resection in Spain (n = 973), the Netherlands (n = 639), or Denmark (n = 280). We evaluated recurrence-free
survival and progression-free survival according to the European Organisation for Research and Treatment of Cancer
(EORTC) and the Spanish Urological Club for Oncological Treatment (CUETO) risk scores for each patient and used the
concordance index (c-index) to indicate discriminative ability.
Results: The 3 cohorts were comparable according to age and sex, but patients from Denmark had a larger proportion of
patients with the high stage and grade at diagnosis (p,0.01). At least one recurrence occurred in 839 (44%) patients and
258 (14%) patients had a progression during a median follow-up of 74 months. Patients from Denmark had the highest 10-
year recurrence and progression rates (75% and 24%, respectively), whereas patients from Spain had the lowest rates (34%
and 10%, respectively). The EORTC and CUETO risk scores both predicted progression better than recurrence with c-indices
ranging from 0.72 to 0.82 while for recurrence, those ranged from 0.55 to 0.61.
Conclusion: The EORTC and CUETO risk scores can reasonably predict progression, while prediction of recurrence is more
difficult. New prognostic markers are needed to better predict recurrence of tumours in primary non-muscle invasive
bladder cancer patients.
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Introduction
Bladder cancer is the most common malignancy of the urinary
tract and a major health issue [1]. Most patients with bladder
cancer are diagnosed with non-muscle invasive disease (NMIBC:
stage Ta or T1) [2]. After transurethral resection (TUR),
recurrence of disease occurs in 30–60% of patients and,
approximately, 10–15% develop progression to muscle-invasive
disease in 5-year after diagnosis [3]. Therefore, regular cystoscopy
is carried out for surveillances after TUR. To better target
surveillance, risk scores for recurrence and progression prediction
have been developed. The best known are the European
Organisation for Research and Treatment of Cancer (EORTC)
[4] and the Spanish Urological Club for Oncological Treatment
(CUETO) [5] risk scores; the latter focusing on BCG treated
patients. Despite their potential usefulness in daily practice, few
studies have externally validated these models [6–11] and no study
focussed on primary NMIBC. In addition, since the EORTC
score was based on a cohort of patients included in 7 clinical trials,
the question arises whether these scores are still valid in a broader
set of NMIBC patients for predictive purposes. The EORTC and
CUETO scores were based on specimens evaluated by central
pathologies and specialized pathologists, whereas the specimens
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included in the present study had been evaluated by routine
pathology. In the present study, we investigated the external
validity of these risk scores in patients with primary NMIBC across
European centres in an everyday routine setting.
Methods
Study Population
We included 1,892 patients with primary NMIBC from three
countries; Spain, Denmark, and the Netherlands. Patients from
Spain were recruited between 1998 and 2001 from 18 general and
University hospitals as part of the Spanish Bladder Cancer/
EPIdemiology of Cancer of the UROthelium (EPICURO) study
[12]. All centres are outlined in Appendix table S1. Patients from
Denmark were selectively included based on being at higher risk of
progression from patient records of the Aarhus University Hospital
between 1979 and 2007 [13]. For the Netherlands, we included
consecutive patients from the Erasmus MC who underwent a
TUR between 1990 and 2012. Patient and tumour characteristics
and data on recurrence and progression after TUR of the primary
NMIBC were extracted from hospital records up till November
2012. All patients had histologically confirmed NMIBC and were
treated according to the centres’ usual procedures. At the Erasmus
MC in the Netherlands, follow-up of patients was according to the
EAU guidelines at the time, and risk-adapted according to the
EORTC risk scores outcome. At the Aarhus University Hospital
in Denmark, the common follow-up strategy for all patients was
every three months. In Spain, protocols for the follow-up of
bladder cancer patients were developed within each centre. For
non-muscle invasive bladder cancers, follow-up for these patients
consisted of bladder endoscopy every three months the first year,
every six months the second year and then annually bladder
endoscopy to complete five years of monitoring. White light
cystoscopy was used in all centres participating in our study.
Disease progression was defined as cystoscopically detected
tumour relapse with histological confirmation at tumour stage T2
or higher (progression to a muscle invasive tumour stage); it was
assumed that a tumour progression always precedes death because
of cancer. Patients that died because of bladder cancer without a
progression were recorded as having had a progression at the time
of death. Recurrence was defined as cystoscopically detected
tumour relapse with histological confirmation. Data from the 3
cohorts were harmonized, anonymized, and combined in one data
set for statistical analyses, stratified by cohort.
All Danish and Spanish patients gave their written informed
consent, and the study was approved by the Central Denmark
Region Committees on Biomedical Research Ethics (1994/2920)
and by the Ethics Committees of each Spanish participating centre
and the Institutional Review Board of the U.S. National Cancer
Institute, NIH, USA. This observational study was exempted from
formal ethical approval in the Netherlands. All data is anonymized
before being used in this study.
Risk Scores
The EORTC scores for recurrence and progression were based
on data from 2,596 patients diagnosed with Ta/T1 tumours from
seven EORTC trials [4]. A limitation of the EORTC scores was
the low number of patients treated with bacillus Calmette Gue´rin
(BCG). Therefore, the CUETO group developed a scoring model
in 1,062 BCG-treated patients [5]. The EORTC score incorpo-
rated the number of tumours (single, 2–7 or $8), tumour size (,
3 cm or $3 cm), prior recurrence rate (primary, #1 recurrence/
year, .1 recurrence/year), T stage (Ta or T1), concomitant
carcinoma in situ (yes/no), and grade (1, 2, or 3). The CUETO
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model incorporated gender, age (,60, 60–70, .70 years),
recurrent tumour (yes/no), number of tumours (#3 or .3), T
stage (Ta or T1), concomitant carcinoma in situ (yes/no), and
grade (1, 2, or 3).
Validation
For all patients, we calculated risks for recurrence and
progression according to the EORTC and CUETO scores based
on the primary tumour. Standard pathologic procedures were
followed in each cohort. Tumour grade was scored according to
the 1973 system, and pathological stage was according to the 2002
staging system. The presence of concomitant carcinoma in situ
was incomplete (CIS, n = 990, 52% missing), as well as data on the
number of tumours (n = 346, 18% missing). We used a multiple
imputation strategy [14] resulting in five sets of complete data to
compute risk scores. We subsequently averaged these risk scores
for each patient. Patient scores were then categorized into four risk
groups, i.e. low, intermediate low, intermediate high, and high risk
for recurrence or progression, as originally specified for the
EORTC and CUETO scores. The two highest risk groups were
combined because of low numbers. Observed recurrence-free
survival (RFS) and progression-free survival (PFS) were calculated
from the date of TUR of the primary tumour. An event for RFS
was defined as recurrence or progression, if progression occurred
as the first event during follow-up. Follow-up was censored at
either the last date of follow-up, the date of death, or 120 months.
We used standard Kaplan–Meier plots to visualize recurrence and
progression patterns in relation to risk groups. This cause-specific
analysis was not adjusted for the competing risk of death before
recurrence or progression, since we focused on the discriminative
ability of the 2 risk scores (quantified by a concordance measure, c-
index) [15]. We conducted subgroup analyses for patients
receiving only BCG treatment after TUR. Furthermore, we
refitted the scores with a Cox regression analysis stratified by
cohort by recalculating risk scores with EORTC and CUETO
coefficients based on our data, to obtain further insight in the
validity of the scores. We used likelihood ratio statistics to
determine the statistical significance of predictors. For compara-
bility with the original EORTC and CUETO scores, we scaled the
refitted regression coefficients by the inverse of the Cox regression
coefficient for the original scores in our data. For example, the
refitted score for T1 vs Ta in the EORTC model for recurrence
was calculated as: multivariable coefficient for T1 vs Ta*1/
(coefficient for EORTC score for recurrence). SPSS (version 20.0,
SPSS Inc, Chicago, Illinois, USA) and R (Version R-2.15.2 for
Windows, http://www.r-project.org/) were used for data analysis.
Results
Study Population
We included 1,892 patients; 280 patients from Denmark, 639
from the Netherlands, and 973 from Spain. During 10 years of
follow-up, 209 (11%) patients died before a recurrence occurred,
839 (44%) patients had a recurrence and 258 (14%) a progression.
Median follow-up for those without recurrence was 74 months.
There were 98 patients (N=90 from the Netherlands, N= 8 from
Denmark) without follow-up because of loss to follow-up
immediately after TUR. CIS (yes/no) and number of tumours
was imputed in patients with missing data, based on 902 patients
Figure 1. A–F. Kaplan-Meier estimates of recurrence of bladder cancer in a ten-year period from transurethral resection of a non-
muscle invasive bladder tumour. Full line: low risk patients, dotted line: intermediate risk patients, dashed line: high risk patients. Number of
patients per country: Denmark n = 280; The Netherlands n = 639; Spain n= 973.
doi:10.1371/journal.pone.0096849.g001
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with information on CIS and 1546 patients with information on
the number of tumours, as well as complete information on
tumour stage, grade, and size, and progression and recurrence free
survival (time and yes/no). The mean age was 66 years and the
majority was male (Table 1). We do not present totals over all
cohorts because of the substantial differences in settings between
cohorts. Danish patients presented a larger proportion of patients
with high stage and grade (P,0.01), and relatively more
recurrences and progressions. The distribution of patients over
the risk groups is shown in table 2.
Validation
The EORTC score could not well separate low risk from high
risk patients with respect to disease recurrence (Figures 1a–c, c-
indices 0.55 to 0.61). Discrimination was somewhat better for
progression (Figures 2a–c, c-indices 0.72 to 0.81). The CUETO
score had a similar performance (figures 1d–f and 2d–f). Subgroup
analyses in patients receiving BCG treatment (n = 449) showed
poorer results (Figures S1a–f and S2a–f).
When we refitted the EORTC score for recurrence in Cox
regression models, the prognostic effects of multiple tumours,
tumour size, CIS and tumour grade were largely confirmed, but
T1 tumours had no increased risk over Ta tumours (Results not
shown). For progression, tumour size and CIS were less predictive
than in the original EORTC score, while the effect for grade was
stronger. For the CUETO score, gender was confirmed to be
predictive of recurrence. While older age was not predictive of
recurrence, we confirmed its value for predicting progression in
the refitted CUETO score (p,0.01).
Discussion
The EORTC risk tables have become a standard of care with
their inclusion in European guidelines [2]. The CUETO risk
model was developed more recently, with a focus on patients
treated with BCG. External validation of a prognostic model on a
new dataset is crucial to assess its generalizability [16]. In our
study, the EORTC and CUETO risk scores showed only modest
discriminative ability for the recurrence of NMIBC, with c-indices
of, at most, 0.61. Prediction of progression was better with c-
indices ranging from 0.72 to 0.82. Our findings were consistent in
the cohorts from Denmark, Spain and the Netherlands, and are in
line with another external validation of the EORTC risk score [6]
and with validation in primary bladder cancer cases [11].
Remarkably, the CUETO score was specifically developed for
patients treated with BCG, but discriminated better in the overall
population than in the selected BCG population. BCG treatment,
which has become a common treatment to manage intermediate-
and high-risk NMIBC [17], was used in 449 patients, of over 50%
at low risk of recurrence and progression according to the
CUETO risk scores. For the EORTC risk scores, we noted that
BCG treatment was usually administered to higher risk patients
with a relatively narrow distribution of risk scores. This
homogeneity in risk may partly explain the poor discriminative
ability of the scores in those treated with BCG [18]. More research
in this specific group of patients needs to be done, also because of
the lack of statistical power due to low numbers of BCG patients in
the current study.
In the original study that presented the EORTC risk scores,
prior recurrence rate was an important prognostic factor for both
Figure 2. A–F. Kaplan-Meier estimates of progression of bladder cancer in a ten-year period from transurethral resection of a non-
muscle invasive bladder tumour. Full line: low risk patients, dotted line: intermediate risk patients, dashed line: high risk patients. Number of
patients per country: Denmark n = 280; The Netherlands n = 639; Spain n= 973.
doi:10.1371/journal.pone.0096849.g002
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recurrence and progression [4]. In the clinical setting, we need to
establish a surveillance plan already after TUR for the primary
tumour. Therefore, it is of great importance that the EORTC risk
score has predictive value also for these patients, who have not had
one or multiple recurrences. We found that predicting recurrence
was very difficult for primary tumours. The heterogeneity in
recurrence risk becomes better known once one or more
recurrences have been observed [19].
A possible explanation for the poor performance of the risk
scores for the prediction of recurrence outside controlled trials is
interobserver variability in bladder cancer staging and grading by
pathologists. To partly overcome these issues, new methods for
bladder cancer pathology have been introduced in 1998 [20] and
2004 [21]. The 1998 method has been shown to be an
improvement over the 1973 method [22], which was used for
our patients.
The poor predictability of recurrence may also relate to other
factors, unrelated to the (observed) pathology of the disease. For
example, detection of all primary tumours may be difficult at
primary tumour presentation. Tumour tissue may be left behind,
falsely leading to classification as a recurrent tumour. The quality
of the TUR may be important but it could not be considered in
our evaluation. Moreover, detection policies may vary between
urologists with respect to surveillance intervals and treatment
modalities (e.g. TUR vs ablation). Progression is a more robust end
point, which may partly explain its better predictability with the
EORTC and CUETO scores.
The retrospective analysis is a limitation of this study, and
explains the presence of missing values in important variables such
as CIS and tumour size. We used multiple imputation, which has
been shown to be a reliable method to handle missing data
[23][23]. We had no detailed information on treatments and
surveillance policies, which may have changed over time. The
treatment modalities may have led to a dilution of differences
between the risk groups. On the other hand, a real life situation
was considered with respect to the standard care of urologists. We
furthermore note that a selected group of high risk patients was
included from Denmark, which can be explained by the fact that
patients originated form a specialised university medical centre.
However, patients from Spain were a representative sample from
standard primary NMIBC population in that country, and patients
from the Netherlands, though originating from an academic
centre, were similar to the general Dutch primary NMIBC patient
population [24].
It is clear that the EORTC and CUETO scores need further
improvement. Several markers have shown promising results, such
as FGFR3 and Ki67, which improved c-indices for prediction of
progression from 0.75 to 0.82 in one study [8]. Various other
promising molecular and germline markers are available, which
need further rigorous evaluation for their usefulness to predict
recurrence and progression [25–26]. Future risk scores will again
need external validation, considering discrimination and other
aspects of predictive performance, such as calibration (correspon-
dence between observed and predicted risks) and clinical
usefulness (ability to make better decisions) [27–29].
We conclude that the discriminatory ability of currently
available risk scores is poor for recurrence and moderate for
progression in primary NMIBC. Since successful discrimination of
low and high risk patients is essential to the right intensity of
bladder cancer surveillance, new risk markers are urgently needed
to improve risk classification in NMIBC patients.
Supporting Information
Figure S1 A–F. Kaplan-Meier estimates of recurrence of
bladder cancer in a ten-year period from transurethral
resection of a bladder tumour for patients with non-
muscle invasive bladder cancer treated with BCG. Full
line: low risk patients, dotted line: intermediate risk patients,
dashed line: high risk patients. Number of patients per country:
Denmark n= 52; The Netherlands n= 108; Spain n= 289.
(TIF)
Figure S2 A–F. Kaplan-Meier estimates of progression
of bladder cancer in a ten-year period from transure-
thral resection of a bladder tumour for patients with
non-muscle invasive bladder cancer treated with BCG.
Full line: low risk patients, dotted line: intermediate risk patients,
dashed line: high risk patients. Number of patients per country:
Denmark n= 52; The Netherlands n= 108; Spain n= 289.
(TIF)
Table S1 Centres and members of the Spanish study
group.
(DOC)
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